Plasmodium falciparum – The Malaria Parasite

What is Plasmodium falciparum?

Plasmodium falciparum is a single-celled parasite (protozoan) and the most deadly of the five Plasmodium species known to infect humans. It is responsible for the majority of malaria-related deaths worldwide and causes the severe form known as falciparum malaria (also called malignant tertian malaria). The disease is most prevalent in sub-Saharan Africa, South Asia, and Southeast Asia, where it remains a major public health challenge.

Causes and Transmission

Plasmodium falciparum is transmitted exclusively through the bite of infected female Anopheles mosquitoes. Direct person-to-person transmission does not occur under normal circumstances, but the parasite can be spread in rare cases via blood transfusions, contaminated needles or syringes, or from mother to unborn child (congenital malaria).

• A mosquito ingests gametocytes (sexual-stage parasites) when feeding on an infected person.
• Sexual reproduction occurs in the mosquito gut, producing infective sporozoites.
• During a subsequent bite, sporozoites are injected into the human bloodstream.
• Sporozoites travel to the liver, where they mature before invading red blood cells.

Life Cycle

The life cycle of Plasmodium falciparum involves two hosts and two main phases:

Phase in the Human Host (Asexual Phase)

After entering the bloodstream, sporozoites invade liver cells (hepatocytes) and develop into merozoites. Unlike other Plasmodium species, P. falciparum does not form dormant liver stages (hypnozoites), so relapses from reactivation do not occur. Merozoites are released into the blood and invade red blood cells (erythrocytes), where they multiply rapidly. The periodic rupture of infected red blood cells releases toxins and triggers the characteristic fever episodes.

Phase in the Mosquito (Sexual Phase)

Some parasites develop into male and female gametocytes in the blood. When ingested by a mosquito, fertilization occurs, and new sporozoites are formed, ready to infect another human host.

Symptoms

The incubation period is typically 7 to 14 days after the infectious mosquito bite. Common symptoms include:

• High fever (often without the regular cyclic pattern seen in other malaria types)
• Chills and sweating
• Severe headache and muscle pain
• Nausea, vomiting, and diarrhea
• Fatigue and dizziness
• Pale or yellowish skin (due to anemia and jaundice)

Without prompt treatment, P. falciparum infection can progress rapidly to life-threatening complications:

• Cerebral malaria: Impaired consciousness, seizures, or coma caused by parasite-clogged brain vessels
• Acute kidney failure
• Severe anemia
• Acute respiratory distress syndrome (ARDS)
• Hypoglycemia (low blood sugar)

Diagnosis

Prompt and accurate diagnosis is essential. Diagnostic methods include:

• Microscopic blood smear: Examination of thick and thin blood smears remains the gold standard for detecting and identifying the parasite
• Rapid diagnostic tests (RDTs): Detect parasite-specific antigens such as HRP-2 (histidine-rich protein 2), which is specific to P. falciparum
• PCR (polymerase chain reaction): Highly sensitive molecular test, especially useful when parasite levels are low
• Blood count, liver function tests, and kidney function tests to assess disease severity

Treatment

Treatment must be initiated as early as possible. The choice of medication depends on disease severity and the geographic region of infection (due to varying resistance patterns):

Uncomplicated Falciparum Malaria

• Artemether/Lumefantrine (e.g., Riamet®): First-line combination therapy
• Atovaquone/Proguanil (e.g., Malarone®): Alternative combination
• Dihydroartemisinin/Piperaquine: Another artemisinin-based combination option

Severe Falciparum Malaria

• Intravenous artesunate: Treatment of choice for severe malaria
• Intravenous quinine plus doxycycline: Alternative if artesunate is unavailable

Due to widespread drug resistance, chloroquine and sulfadoxine/pyrimethamine are no longer recommended for treating P. falciparum infections in most endemic regions.

Prevention and Prophylaxis

Travelers to malaria-endemic areas should take the following precautions:

• Personal protection: Use of insect repellents, long-sleeved clothing, bed nets (preferably insecticide-treated)
• Chemoprophylaxis: Depending on the destination, options include atovaquone/proguanil, mefloquine, or doxycycline
• Vaccination: The RTS,S/AS01 vaccine (Mosquirix®) is approved for young children in sub-Saharan Africa and provides partial protection against P. falciparum

References

1. World Health Organization (WHO): World Malaria Report 2023. Geneva: WHO, 2023. Available at: https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2023
2. Centers for Disease Control and Prevention (CDC): Malaria – Biology. Atlanta: CDC, 2023. Available at: https://www.cdc.gov/malaria/about/biology/index.html
3. Trampuz A, Jereb M, Muzlovic I, Prabhu RM: Clinical review – Severe malaria. Critical Care, 2003; 7(4): 315–323. PubMed PMID: 12930555.